The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B

Influence of sequential adefovir-refractoriness

Jung Ho Kim, Yun Soo Kim, Young Kul Jung, Yeon Suk Kim, Oh Sang Kwon, Yang Sun Ku, Duck Joo Choi, Ju Hyun Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: Sequential antiviral therapy for chronic hepatitis B may lead to the selection of multidrug-resistant mutation. This study was carried out to assess the efficacy of entecavir in patients that have experienced adefovir monotherapy failure after the development of lamivudine resistance. Methodology: Fifty-three patients with confirmed genotypic lamivudine-resistant chronic hepatitis B were treated with entecavir. Thirty patients were switched to entecavir directly (LAM-ETV group), whereas the remaining 23 were adefovir-refractory patients who were switched to entecavir (LAM-ADV-ETV group). These 23 patients included 9 patients with inadequate response (ADV-I subgroup) and 14 that exhibited adefovir resistance (ADV-R subgroup). Results: Significantly greater reductions in HBV DNA levels were observed after 24, 48 and 72 weeks of entecavir therapy in the LAM-ETV group than in the LAM-ADV-ETV group, respectively. However, between these two groups at 48 and 72 weeks, no significant differences were observed in cumulative proportions of virological response or breakthrough, respectively. Furthermore, efficacy of entecavir was not significantly different in the ADV-I and ADV-R subgroups. Four patients in the LAM-ETV group and six patients in the LAM-ADV-ETV group developed genotypic resistance to entecavir. Conclusions: Entecavir therapy is less effective in adefovir-refractory patients with prior lamivudine resistance than in lamivudine-resistant patients.

Original languageEnglish
Pages (from-to)842-849
Number of pages8
JournalHepato-Gastroenterology
Volume60
Issue number124
DOIs
Publication statusPublished - 2013 Jun 1
Externally publishedYes

Fingerprint

Lamivudine
Chronic Hepatitis B
adefovir
entecavir
Antiviral Agents
lipoarabinomannan
Therapeutics
Mutation

Keywords

  • Adefovir
  • Chronic hepatitis B
  • Drug resistance
  • Entecavir
  • Lamivudine
  • Treatment failure

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B : Influence of sequential adefovir-refractoriness. / Kim, Jung Ho; Kim, Yun Soo; Jung, Young Kul; Kim, Yeon Suk; Kwon, Oh Sang; Ku, Yang Sun; Choi, Duck Joo; Kim, Ju Hyun.

In: Hepato-Gastroenterology, Vol. 60, No. 124, 01.06.2013, p. 842-849.

Research output: Contribution to journalArticle

Kim, Jung Ho ; Kim, Yun Soo ; Jung, Young Kul ; Kim, Yeon Suk ; Kwon, Oh Sang ; Ku, Yang Sun ; Choi, Duck Joo ; Kim, Ju Hyun. / The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B : Influence of sequential adefovir-refractoriness. In: Hepato-Gastroenterology. 2013 ; Vol. 60, No. 124. pp. 842-849.
@article{d5ef4266795b4f0c86ea2510562e9794,
title = "The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: Influence of sequential adefovir-refractoriness",
abstract = "Background/Aims: Sequential antiviral therapy for chronic hepatitis B may lead to the selection of multidrug-resistant mutation. This study was carried out to assess the efficacy of entecavir in patients that have experienced adefovir monotherapy failure after the development of lamivudine resistance. Methodology: Fifty-three patients with confirmed genotypic lamivudine-resistant chronic hepatitis B were treated with entecavir. Thirty patients were switched to entecavir directly (LAM-ETV group), whereas the remaining 23 were adefovir-refractory patients who were switched to entecavir (LAM-ADV-ETV group). These 23 patients included 9 patients with inadequate response (ADV-I subgroup) and 14 that exhibited adefovir resistance (ADV-R subgroup). Results: Significantly greater reductions in HBV DNA levels were observed after 24, 48 and 72 weeks of entecavir therapy in the LAM-ETV group than in the LAM-ADV-ETV group, respectively. However, between these two groups at 48 and 72 weeks, no significant differences were observed in cumulative proportions of virological response or breakthrough, respectively. Furthermore, efficacy of entecavir was not significantly different in the ADV-I and ADV-R subgroups. Four patients in the LAM-ETV group and six patients in the LAM-ADV-ETV group developed genotypic resistance to entecavir. Conclusions: Entecavir therapy is less effective in adefovir-refractory patients with prior lamivudine resistance than in lamivudine-resistant patients.",
keywords = "Adefovir, Chronic hepatitis B, Drug resistance, Entecavir, Lamivudine, Treatment failure",
author = "Kim, {Jung Ho} and Kim, {Yun Soo} and Jung, {Young Kul} and Kim, {Yeon Suk} and Kwon, {Oh Sang} and Ku, {Yang Sun} and Choi, {Duck Joo} and Kim, {Ju Hyun}",
year = "2013",
month = "6",
day = "1",
doi = "10.5754/hge12917",
language = "English",
volume = "60",
pages = "842--849",
journal = "Hepato-Gastroenterology",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "124",

}

TY - JOUR

T1 - The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B

T2 - Influence of sequential adefovir-refractoriness

AU - Kim, Jung Ho

AU - Kim, Yun Soo

AU - Jung, Young Kul

AU - Kim, Yeon Suk

AU - Kwon, Oh Sang

AU - Ku, Yang Sun

AU - Choi, Duck Joo

AU - Kim, Ju Hyun

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Background/Aims: Sequential antiviral therapy for chronic hepatitis B may lead to the selection of multidrug-resistant mutation. This study was carried out to assess the efficacy of entecavir in patients that have experienced adefovir monotherapy failure after the development of lamivudine resistance. Methodology: Fifty-three patients with confirmed genotypic lamivudine-resistant chronic hepatitis B were treated with entecavir. Thirty patients were switched to entecavir directly (LAM-ETV group), whereas the remaining 23 were adefovir-refractory patients who were switched to entecavir (LAM-ADV-ETV group). These 23 patients included 9 patients with inadequate response (ADV-I subgroup) and 14 that exhibited adefovir resistance (ADV-R subgroup). Results: Significantly greater reductions in HBV DNA levels were observed after 24, 48 and 72 weeks of entecavir therapy in the LAM-ETV group than in the LAM-ADV-ETV group, respectively. However, between these two groups at 48 and 72 weeks, no significant differences were observed in cumulative proportions of virological response or breakthrough, respectively. Furthermore, efficacy of entecavir was not significantly different in the ADV-I and ADV-R subgroups. Four patients in the LAM-ETV group and six patients in the LAM-ADV-ETV group developed genotypic resistance to entecavir. Conclusions: Entecavir therapy is less effective in adefovir-refractory patients with prior lamivudine resistance than in lamivudine-resistant patients.

AB - Background/Aims: Sequential antiviral therapy for chronic hepatitis B may lead to the selection of multidrug-resistant mutation. This study was carried out to assess the efficacy of entecavir in patients that have experienced adefovir monotherapy failure after the development of lamivudine resistance. Methodology: Fifty-three patients with confirmed genotypic lamivudine-resistant chronic hepatitis B were treated with entecavir. Thirty patients were switched to entecavir directly (LAM-ETV group), whereas the remaining 23 were adefovir-refractory patients who were switched to entecavir (LAM-ADV-ETV group). These 23 patients included 9 patients with inadequate response (ADV-I subgroup) and 14 that exhibited adefovir resistance (ADV-R subgroup). Results: Significantly greater reductions in HBV DNA levels were observed after 24, 48 and 72 weeks of entecavir therapy in the LAM-ETV group than in the LAM-ADV-ETV group, respectively. However, between these two groups at 48 and 72 weeks, no significant differences were observed in cumulative proportions of virological response or breakthrough, respectively. Furthermore, efficacy of entecavir was not significantly different in the ADV-I and ADV-R subgroups. Four patients in the LAM-ETV group and six patients in the LAM-ADV-ETV group developed genotypic resistance to entecavir. Conclusions: Entecavir therapy is less effective in adefovir-refractory patients with prior lamivudine resistance than in lamivudine-resistant patients.

KW - Adefovir

KW - Chronic hepatitis B

KW - Drug resistance

KW - Entecavir

KW - Lamivudine

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=84879585478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879585478&partnerID=8YFLogxK

U2 - 10.5754/hge12917

DO - 10.5754/hge12917

M3 - Article

VL - 60

SP - 842

EP - 849

JO - Hepato-Gastroenterology

JF - Hepato-Gastroenterology

SN - 0172-6390

IS - 124

ER -